TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

Germline testing is a genetic screening that looks for inherited gene mutations found in every cell.  It can identify ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Add Yahoo as a preferred source to see more of our stories on Google. Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the ...